Hadassah follows US centers in using embryonic stem cell for optical procedures

The Health Ministry approved the experimental use to treat AMD for the first time following years in which embryonic stem cells were not found effective

September 3, 2015 09:04
1 minute read.
eye exam

Eye exam [Illustrative]. (photo credit: REUTERS)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Following several attempts by US researchers, ophthalmologists at the Hadassah University Medical Center in Jerusalem’s Ein Kerem have become the first in Israel to implant retinal-pigment epithelial (RPE) cells derived from embryonic stem cells into a patient with severe age-related macular degeneration (AMD). Hadassah ophthalmologists said they were implanting the cells in the hope of eventually finding an effective treatment for the degenerative disease.

The Health Ministry approved the experimental use to treat AMD for the first time following years in which embryonic stem cells were not found effective. The Hadassah attempt involved the implantation of retinal pigment cells to replace the degenerated retinal cells in the patient, but nowhere in the world has it yet proved to relieve the condition.

Be the first to know - Join our Facebook page.

AMD is the most common cause of low vision in the Western world and severely reduces the quality of life of affected elderly people. It damages the macular region of the retina, which is vital for sharpness in the center of the eye’s field of vision. In the US alone, 1.6 million people per year are diagnosed with the condition. It results from the death of pigment cells found under the retina.

Human embryonic stem cells, however, can multiply endlessly in the lab and be a reliable source for healthy pigment cells for the retina. Implantation of such cells, Hadassah ophthalmologists hope, may eventually halt or slow the advance of AMD.

The research group that worked on the potential breakthrough is headed by Prof. Benjamin Reubinoff, head of Hadassah’s embryonic stem cell research center and director of obstetrics/gynecology department in the Ein Kerem hospital, along with Prof. Eyal Banin, head of degenerative diseases of the Retina and Macular Center in the hospital’s ophthalmology department. The two have cooperated for more than a decade to create conditions for the ripening of embryonic stem cells into pigment cells for the retina, together with Cell Cure Neurosciences Ltd.

“This transplantation is the initial step in a trial that will include the transplantation to additional patients and will be among the very few similar pioneer clinical trials worldwide. The goal of this trial is primarily to ensure the safety of transplantation of the cells, and also to evaluate parameters of therapeutic effects, according to Reubinoff.

Related Content

CANCER PATIENTS sit in a chemotherapy ward while receiving treatment at the Korle Bu Teaching Hospit
August 15, 2018
Cancer as a chronic illness